TSHA — TAYSHA GENE THERAPIES INC (Healthcare >> Biotechnology)
TSHA FAQ
What is TSHA's ROE?
TAYSHA GENE THERAPIES INC reports a Return on Equity (ROE) of -61.28%.
What is TSHA's dividend yield?
TAYSHA GENE THERAPIES INC offers a dividend yield of 0.00%.
What is TSHA's Deepscope Quality Score?
Deepscope rates TSHA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TSHA?
Deepscope's AI Timing Score for TSHA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TSHA belong to?
TAYSHA GENE THERAPIES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.71
Price
0.13
(2.33%)
Day Change
|
|
|---|
TSHA Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 15) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.71 |
| PBV / Sector |
7.57 / 4.91
|
| Earning Per Share | -0.46 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
11.80 M
GREAT
|
| Average 1W Daily Value |
13.52 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
64% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:03 |
| Symbol | TSHA |
| Name | TAYSHA GENE THERAPIES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 287.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,603.47 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
Phone: 214 612 0000
Website: https://www.tayshagtx.com
Employees: 99
Sector: Healthcare >> Biotechnology
Description: Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google